Viridian Therapeutics (VRDN) revenue breakdown
By product, License is the largest at 99% of fiscal 2025 revenue.
Revenue by product
Fiscal years, as Viridian Therapeutics reports them in its 10-K filings; fiscal 2025 total $71M.
| Products | 2017 | 2018 | 2019 | 2020 | 2025 | Share |
|---|---|---|---|---|---|---|
| License | — | — | — | — | $70M | 99% |
| Collaboration | $3M | $7M | $4M | $735,000 | $849,000 | 1% |
| Grant revenue | $906,000 | $1M | $153,000 | $315,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VRDN.
Open VRDN in InvestinglyQuestions
Where does Viridian Therapeutics make its money?
In fiscal 2025, by product: License $70M, Collaboration $849,000.
From Viridian Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.